CN111803624A - 一种含有转移因子的皮肤抗菌凝胶制剂和制备方法 - Google Patents
一种含有转移因子的皮肤抗菌凝胶制剂和制备方法 Download PDFInfo
- Publication number
- CN111803624A CN111803624A CN202010730705.4A CN202010730705A CN111803624A CN 111803624 A CN111803624 A CN 111803624A CN 202010730705 A CN202010730705 A CN 202010730705A CN 111803624 A CN111803624 A CN 111803624A
- Authority
- CN
- China
- Prior art keywords
- skin
- transfer factor
- parts
- gel
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 50
- 108010074506 Transfer Factor Proteins 0.000 title claims abstract description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 41
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000000284 extract Substances 0.000 claims abstract description 29
- 239000011159 matrix material Substances 0.000 claims abstract description 23
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 14
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 14
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 13
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940116229 borneol Drugs 0.000 claims abstract description 13
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940041616 menthol Drugs 0.000 claims abstract description 13
- 238000012546 transfer Methods 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 7
- 230000001376 precipitating effect Effects 0.000 claims abstract description 3
- 238000004140 cleaning Methods 0.000 claims abstract 2
- 238000003756 stirring Methods 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000005303 weighing Methods 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000084 colloidal system Substances 0.000 claims description 10
- 238000011049 filling Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
- 230000008961 swelling Effects 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 6
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 6
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims description 5
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 5
- 241001671204 Stemona Species 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000212948 Cnidium Species 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims 5
- 241000110847 Kochia Species 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000643 oven drying Methods 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract description 10
- 239000005556 hormone Substances 0.000 abstract description 7
- 229940088597 hormone Drugs 0.000 abstract description 7
- 241000628997 Flos Species 0.000 abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 239000002344 surface layer Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 235000011187 glycerol Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010040880 Skin irritation Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 238000004042 decolorization Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 206010063409 Acarodermatitis Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000447727 Scabies Species 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- -1 polyhexamethylene guanidine Polymers 0.000 description 3
- 208000005687 scabies Diseases 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Natural products C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种含有转移因子的皮肤抗菌凝胶制剂和制备方法,属于消毒技术领域。所述凝胶制剂的原料组成和重量份数为:中药提取物1份、转移因子0.4‑0.8份、醋酸氯己定0.2‑0.5份、薄荷脑0.3‑0.6份、冰片0.1份、甘油12‑15份、丙二醇12‑15份、凝胶基质67‑74份。其中中药提取物由牡丹皮、百部、苦参、蛇床子、地肤子和野菊花六种中药材经煎煮、醇沉、脱色获得。本发明所述含转移因子的皮肤抗菌凝胶制剂有助于维护皮肤表层微环境,促进皮肤免疫力恢复;不含抗生素和激素,不易产生耐药性,可长期使用;且抗菌效果明显、对皮肤无刺激性、安全稳定;适用于皮肤感染后的抗菌消炎、清洁护理等。
Description
技术领域
本发明属于消毒技术领域,尤其涉及一种含有转移因子的皮肤抗菌凝胶制剂和制备方法。
背景技术
人体皮肤是机体抵御体外微生物感染的一道天然屏障。由于受伤、免疫功能异常等原因,皮肤往往容易受到细菌、真菌、病毒等微生物的感染而引发各种皮肤病。传统的皮肤抗菌剂,按组成成分大多为化学抗菌剂,如季铵盐类(以苯扎氯铵、苯扎溴铵为代表)、胍类消毒剂(以氯已定、聚六亚甲基胍为代表)以及过氧化氢、碘伏、三氯羟基二苯醚(三氯生)等,单一成分的化学消毒剂存在安全性隐患,且功能单一,容易产生耐药性,对耐药菌株无效。近些年,一些具有抑菌作用的中药提取物复方制剂相继问世,而中药复方制剂起效慢,抗菌抑菌效果不理想。对于因过敏或者免疫功能异常所引发的皮肤感染来说,化学抗菌剂和中药复方抗菌制剂都不能达到很好的治疗效果,临床上往往会使用激素类外用皮肤制剂配合治疗,反复使用激素类制剂又会使局部抵抗力降低,病情加重,治标不治本,导致皮肤感染病程迁延,反复发作。因此,市场上亟需一种多组分、无激素、安全有效的皮肤抗菌制剂。
转移因子是机体免疫应答过程中,由T淋巴细胞释放的一种细胞因子,能够将供体的细胞免疫信息特异地转移给受体细胞,从而增强受体的免疫功能。作为一种免疫调节药,转移因子可增强或抑制体液免疫和细胞免疫功能,增加助性T细胞数,在临床上广泛用于细菌性疾病、病毒性疾病、真菌性疾病等疾病防治。对于抗生素、抗病毒药物难以控制的皮肤感染疾病,临床上常用转移因子制剂作为辅助用药,配合抗菌治疗。目前已有注射用转移因子、转移因子胶囊、转移因子口服液等剂型,尚无转移因子外用制剂。所以,临床需要一种组方抗菌制剂,既能发挥传统抗菌制剂短期抗菌效果明显优势,又能体现中药复方制剂抗菌消炎、祛湿止痒、安全无副作用的特点,同时还能调节受损皮肤免疫功能,达到标本兼治的目的。
发明内容
本发明提供一种含有转移因子的皮肤抗菌凝胶制剂和制备方法。目的在于:解决化学抗菌剂功能单一、容易产生耐药性,而中药复方制剂抗菌效果差、激素类制剂毒副反应多的问题,同时解决传统抗菌制剂治标不治本的问题。
为了达到如上目的,本发明采取如下技术方案:
一种含有转移因子的皮肤抗菌凝胶制剂,其特征在于原料组成和重量份数为:中药提取物1份、转移因子0.4-0.8份、醋酸氯已定0.2-0.5份、薄荷脑0.3-0.6份、冰片0.1份、甘油12-15份、丙二醇12-15份、凝胶基质67-74份。
本发明进一步技术方案在于,所述的中药提取物由牡丹皮、百部、苦参、蛇床子、地肤子和野菊花六种中药材中提取制成。其中牡丹皮具有清热凉血、活血化瘀等功效(《神农本草经》)。牡丹皮提取物具有抗菌抗炎、止血镇痛、消热消肿等作用(《中药现代研究与应用》)。牡丹皮的主要有效成分丹皮酚还具有抑制细胞内O2-自由基产生,能使皮肤增白,将皮肤中沉积色素还原褪色,对色斑、皮肤瘙痒、牛皮癣、带状疮疹、湿疹具有较好的治疗和保健效果,丹皮酚在皮肤外用制剂中已经广泛使用;百部“火炙浸酒空腹饮,去虫蚕咬,兼疥癣疮”(《本草拾遗》),体外试验表明:百部煎剂及醇浸剂对多种细菌、病毒、致病真菌具有抑制作用;苦参具“凉血、解热毒、疥癞、脓疮毒。疗皮肤瘙痒、血风癣疮、顽皮白屑”(《滇南本草》);地肤子能“去皮肤中积热,除皮肤外湿痒”(《本草原始》);野菊花能疏风清热,消肿解毒,“用于痈疽疔肿化脓病”(《现代实用中药》)。六味中药配伍使用,最大性能地发挥抗菌消炎、祛湿消肿、止痒镇痛等作用。
本发明中的冰片、薄荷脑起到清凉止痛、生肌收口作用,有利于受损皮肤的修复。
本发明中的醋酸氯已定为双胍类阳离子表面活性剂,是常用的外用抗菌消毒剂,具有广谱抑菌、杀菌作用,对革兰阳性菌及革兰阴性菌均有效。其特点是高效安全、副作用小。醋酸氯已定与中药提取物协同作用,进一步增强抗菌效果。
本发明中的转移因子作为免疫调节剂,能有效纠正机体过敏及调节免疫功能紊乱,对湿疹、过敏性皮炎、不明原因的瘙痒和病毒感染性皮肤病的受损免疫状态进行修复调整,进而维持皮肤的正常免疫状态。配伍中加入转移因子稳定抗菌效果,进一步解决病程迁延和反复发作的问题。
本发明中的甘油和丙二醇,起溶剂、软化剂和保湿剂作用,也能够使皮肤保持柔软,富有弹性,不干燥,防止皮肤皲裂。
本发明进一步技术方案在于,本发明采用凝胶剂。凝胶基质为羟丙甲纤维素(或其它甲基纤维素衍生物)充分溶胀于去离子水中制成,羟丙甲纤维素含量为3-5%。
本发明进一步技术方案在于,中药提取物由如下重量比的中药材经煎煮、醇沉、脱色获得。重量比为:牡丹皮10∶百部5∶苦参1∶蛇床子1∶地肤子1∶野菊花1。
本发明进一步技术方案在于,转移因子用健康的猪或牛脾脏为原料,经去脂肪、细胞破碎、透析或超滤制成的分子量小于6kDa的多肽、氨基酸和多核苷酸的混合物溶液,再经过冷冻干燥制成。其含多肽应大于80mg/kg,含核苷酸以D-核糖计应不低于3mg/kg。
本发明所述含有转移因子的皮肤抗菌凝胶制剂和制备方法,其特征在于,一种含有转移因子的皮肤抗菌凝胶制剂的制备方法包括以下步骤:
步骤1,中药提取物的制备:按原料重量份计取各干燥中药组分粉碎成粉,混合后加入10倍量的水煎煮,煎煮后提取上清液浓缩,再加乙醇至含醇量约为65%,用水溶解后加入活性炭脱色,过滤后再加乙醇至含醇量约为65%,静置、过滤,取沉淀烘干后为所述的中药提取物;
步骤2,凝胶基质配制:称取羟丙甲纤维素,与相应比例的去离子水搅拌混合,使羟丙甲纤维素含量为3-5%,充分溶胀静置24h制得透明胶体,为所述的凝胶基质;
步骤3,称取1份步骤1项中药提取物、0.4-0.8份转移因子、0.2-0.5份醋酸氯已定、0.3-0.6份薄荷脑、0.1份冰片、12-15份甘油、12-15份丙二醇,混合搅拌为均匀的混合液;
步骤4,取步骤2项中的凝胶基质67-74份,与步骤3混合液混合搅拌,研磨乳化,形成均一稳定的粘稠状胶体,静置24h后,即为含有转移因子的皮肤抗菌凝胶;
步骤5,灌装:灌装容器脱包清洁后,用紫外线灭菌30min后,定量灌装,含转移因子的皮肤抗菌凝胶制剂制备完成。
本发明进一步技术方案在于,所述凝胶剂的pH为5.0-8.0。
采用如上技术方案的本发明,相对于现有技术有如下有益效果:
(1)本发明通过中药提取物、醋酸氯已定、转移因子成分、薄荷脑、冰片配伍,同时,以甘油、丙二醇为佐剂制成凝胶剂。为中西医结合复方制剂,标本兼治,抗菌消炎效果显著提高;
(2)本发明不含抗生素和激素,不产生抗生素耐药性问题,也无激素产生的副作用,比抗生素制剂和激素类制剂更安全;
(3)本发明所用凝胶剂涂展性好,有效成分分散均匀,使给药率提高。且易分散于皮肤表面形成保护膜,起到保护受损皮肤的作用,提高使用者的依从性;
(4)本发明制备方法简单方便、制备过程中采用的各种原辅料容易获取,分布广泛,易于控制并可进行大规模生产。
具体实施方式
下面结合具体实施方式,进一步阐明本发明,应理解下述具体实施方式仅用于说明本发明而不用于限制本发明的范围。
实施例1本实施例含有转移因子的皮肤抗菌凝胶制剂,由以下重量的原料制成:中药提取物100g、转移因子60g、醋酸氯已定40g、薄荷脑50g、冰片10g、甘油1400g、丙二醇1500g、凝胶基质6.8kg。
本实施例的含有转移因子的皮肤抗菌凝胶制剂的制备方法包括如下步骤:
(1)中药提取物的制备:取干燥的牡丹皮1kg、百部0.5kg、苦参0.1kg、蛇床子0.1kg、地肤子0.1kg、野菊花0.1kg,混合后粉碎成粉,加19kg水进行煎煮,煎煮后提取上清液浓缩,再加乙醇至含醇量约为65%,用水溶解后加入活性炭脱色,过滤后再加乙醇至含醇量约为65%,静置、过滤,取沉淀烘干后为所述的中药提取物;
(2)凝胶基质配制:称取300g羟丙甲纤维素,与6500g去离子水搅拌混合,溶胀静置24h制得透明胶体,为所述的凝胶基质;
(3)称取(1)项中药提取物100g,并称量上述数量的甘油、丙二醇、冰片、薄荷脑、醋酸氯已定、转移因子等,混合搅拌,成为均匀的混合液;
(4)将(3)项中的混合液加入(2)项中的凝胶基质中,边加边搅拌,搅拌均匀后研磨乳化成均一稳定的粘稠状胶体,为含有转移因子的皮肤抗菌凝胶;
(5)灌装:容器脱包清洁后,用紫外线灭菌30min后灌装,即含有转移因子的皮肤抗菌凝胶制剂制备完成。
检测pH值为6.7。
实施例2本实施例含有转移因子的皮肤抗菌凝胶制剂,由以下重量的原料制成:中药提取物100g、转移因子40g、醋酸氯已定30g、薄荷脑30g份、冰片10g份、甘油1500g份、丙二醇1300g份、凝胶基质7.0kg。
本实施例的含有转移因子的皮肤抗菌凝胶制剂的制备方法包括如下步骤:
(1)中药提取物的制备:取干燥的牡丹皮1kg、百部0.5kg、苦参0.1kg、蛇床子0.1kg、地肤子0.1kg、野菊花0.1kg,混合后粉碎成粉,加19kg水进行煎煮,煎煮后提取上清液浓缩,再加乙醇至含醇量约为65%,用水溶解后加入活性炭脱色,过滤后再加乙醇至含醇量约为65%,静置、过滤,取沉淀烘干后为所述的中药提取物;
(2)凝胶基质配制:称取300g羟丙甲纤维素,与6700g去离子水搅拌混合,溶胀静置24h制得透明胶体,为所述的凝胶基质;
(3)称取(1)项中药提取物100g,并称量上述数量的甘油、丙二醇、冰片、薄荷脑、醋酸氯已定、转移因子成分等,混合搅拌,成为均匀的混合液;
(4)将(3)项中的混合液加入(2)项中的凝胶基质中,边加边搅拌,搅拌均匀后研磨乳化成均一稳定的粘稠状胶体,为含有转移因子的皮肤抗菌凝胶;
(5)灌装:容器脱包清洁后,用紫外线灭菌30min后灌装,即含有转移因子的皮肤抗菌凝胶制剂制备完成。
检测pH值为6.5。
实施例3本实施例含有转移因子的皮肤抗菌凝胶制剂,由以下重量的原料制成:中药提取物100g、转移因子80g、醋酸氯已定50g、薄荷脑40g份、冰片10g份、甘油1200g份、丙二醇1400g份、凝胶基质7.1kg。
本实施例的含有转移因子的皮肤抗菌凝胶制剂的制备方法包括如下步骤:
(1)中药提取物的制备:取干燥的牡丹皮1kg、百部0.5kg、苦参0.1kg、蛇床子0.1kg、地肤子0.1kg、野菊花0.1kg,混合后粉碎成粉,加19kg水进行煎煮,煎煮后提取上清液浓缩,再加乙醇至含醇量约为65%,用水溶解后加入活性炭脱色,过滤后再加乙醇至含醇量约为65%,静置、过滤,取沉淀烘干后为所述的中药提取物;
(2)凝胶基质配制:称取350g羟丙甲纤维素,与6750g去离子水搅拌混合,溶胀静置24h制得透明胶体,为所述的凝胶基质;
(3)称取(1)项中药提取物100g,并称量上述数量的甘油、丙二醇、冰片、薄荷脑、醋酸氯已定、转移因子等,混合搅拌,成为均匀的混合液;
(4)将(3)项中的混合液加入(2)项中的凝胶基质中,边加边搅拌,搅拌均匀后研磨乳化成均一稳定的粘稠状胶体,为含有转移因子的皮肤抗菌凝胶;
(5)灌装:容器脱包清洁后,用紫外线灭菌30min后灌装,即含转移因子的皮肤抗菌凝胶制剂制备完成。
检测pH值为6.3。
实施例4对实施例1、实施例2、实施例3中所制备的含有转移因子的皮肤抗菌凝胶制剂进行测试。经陕西医药控股集团医药研究院和陕西省保健品检测中心检测,数据如下:
1.抗菌效果:
按照GB15979-2002《一次性使用卫生用品卫生标准》进行,抑菌试验为载体试验,试验温度为20±1℃,试验重复三次。作用10min,平均抑菌率如下表所示:
从表中可以看出,对于金黄色葡萄球菌、大肠杆菌和白色念珠菌,皮肤抗菌剂均能够在10min内达到100%的杀灭率。
2.安全性:
2.1多次皮肤刺激实验
按照《消毒技术规范》中多次皮肤刺激试验方法,实施例1、实施例2、实施例3所制含有转移因子的皮肤抗菌凝胶制剂多次皮肤刺激,最高刺激指数评分均为0,根据《消毒技术规范》中皮肤刺激强度分级标准,试验结果为多次皮肤刺激强度属无刺激性。
2.2铅汞砷含量测定
按《化妆品安全技术规范》2015年版有关方法测定。铅汞砷含量如下表所示:
3.稳定性:
按照GB15979《一次性使用卫生用品卫生标准》方法进行。样品在稳定性试验条件(37℃~40℃,相对湿度≥75%,保存3个月后)后进行试验,试验温度为20±1℃,试验重复三次。作用10min,平均抑菌率如下表:
从表中数据可见,皮肤抗菌剂的稳定性良好。本发明的复合抗菌剂的杀菌或抑菌作用在室温下可至少保持二年。
以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本领域的技术人员应该了解本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的范围内。
Claims (7)
1.一种含有转移因子的皮肤抗菌凝胶制剂,其特征在于原料组成和重量份数为:中药提取物1份、转移因子0.4-0.8份、醋酸氯己定0.2-0.5份、薄荷脑0.3-0.6份、冰片0.1份、、甘油12-15份、丙二醇12-15份、凝胶基质67-74份。
2.如权利要求1所述的一种含有转移因子的皮肤抗菌凝胶制剂,其特征在于:所述的中药提取物由牡丹皮、百部、苦参、蛇床子、地肤子和野菊花六种中药材提取而成。
3.如权利要求1所述的一种含有转移因子的皮肤抗菌凝胶制剂,其特征在于:所述的转移因子用健康的猪或牛脾脏为原料,经去脂肪、细胞破碎、透析或超滤制成的分子量小于6kDa的多肽、氨基酸和多核苷酸的混合物溶液,再经过冷冻干燥制成;其含多肽应大于80mg/kg,含核苷酸以D-核糖计应不低于3mg/kg。
4.如权利要求1所述的一种含有转移因子的皮肤抗菌凝胶制剂,其特征在于:所述的凝胶基质为羟丙甲纤维素在去离子水中充分溶胀后获得,羟丙甲纤维素含量为3-5%。
5.如权利要求1所述的一种含有转移因子的皮肤抗菌凝胶制剂,其特征在于:所述凝胶剂的pH为5.0-8.0。
6.如权利要求2所述的一种含有转移因子的皮肤抗菌凝胶制剂,其特征在于:所述的中药提取物由如下重量比的干燥中药材经煎煮、醇沉、脱色获得;重量比为:牡丹皮10:百部5:苦参1:蛇床子1:地肤子1:野菊花1。
7.如权利要求1-6任一项所述的含有转移因子的皮肤抗菌凝胶制剂的制备方法,其特征在于包括如下步骤:
步骤1,中药提取物的制备:按原料重量份计取各干燥中药组分粉碎成粉,混合后加入10倍量的水煎煮,煎煮后提取上清液浓缩,再加乙醇至含醇量约为65%;用水溶解后加入活性炭脱色,过滤后再加乙醇至含醇量约为65%;静置、、过滤,取沉淀烘干后为所述的中药提取物;
步骤2,凝胶基质的配制:称取羟丙甲纤维素,与相应比例的去离子水搅拌混合,使羟丙甲纤维素含量为3-5%,充分溶胀静置24h制得透明胶体,为所述的凝胶基质;
步骤3,称取1份步骤1项的中药提取物、0.4-0.8份转移因子、0.2-0.5份醋酸氯己定、0.3-0.6份薄荷脑、0.1份冰片、12-15份甘油和12-15份丙二醇,混合搅拌为均匀的混合液;
步骤4,取步骤2项中的凝胶基质67-74份,与步骤3混合液混合搅拌,研磨乳化,形成均一稳定的粘稠状胶体,静置24h后,即为含有转移因子的皮肤抗菌凝胶;
步骤5,灌装:灌装容器脱包清洁,用紫外线灭菌30min后,定量灌装,含转移因子的皮肤抗菌凝胶制剂制备完成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010730705.4A CN111803624A (zh) | 2020-07-27 | 2020-07-27 | 一种含有转移因子的皮肤抗菌凝胶制剂和制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010730705.4A CN111803624A (zh) | 2020-07-27 | 2020-07-27 | 一种含有转移因子的皮肤抗菌凝胶制剂和制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111803624A true CN111803624A (zh) | 2020-10-23 |
Family
ID=72861235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010730705.4A Pending CN111803624A (zh) | 2020-07-27 | 2020-07-27 | 一种含有转移因子的皮肤抗菌凝胶制剂和制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111803624A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113456616A (zh) * | 2021-07-09 | 2021-10-01 | 潮州市亿生健医药保健品有限公司 | 一种基于聚六亚甲基胍的消毒用涂膜剂及其制备方法 |
| CN114832140A (zh) * | 2022-05-06 | 2022-08-02 | 江苏益仁堂生物科技有限公司 | 一种医用皮肤修复敷料配方 |
| CN118059159A (zh) * | 2024-04-22 | 2024-05-24 | 科曼尼(吉林)生物科技有限公司 | 一种中药皮肤抗菌凝胶及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009069906A1 (en) * | 2007-11-30 | 2009-06-04 | Amorepacific Corporation | Composition for skin external application containing complex of herbal extracts |
| CN102755275A (zh) * | 2012-07-24 | 2012-10-31 | 河南华美生物工程有限公司 | 一种植物提取物干洗消毒凝胶 |
| CN103705539A (zh) * | 2013-12-30 | 2014-04-09 | 天津瑞普生物技术股份有限公司 | 一种猪脾转移因子制备方法 |
| CN107812137A (zh) * | 2017-10-25 | 2018-03-20 | 北京中蜜科技发展有限公司 | 一种含蜂胶的草本皮肤抑菌凝胶及其制备方法 |
-
2020
- 2020-07-27 CN CN202010730705.4A patent/CN111803624A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009069906A1 (en) * | 2007-11-30 | 2009-06-04 | Amorepacific Corporation | Composition for skin external application containing complex of herbal extracts |
| CN102755275A (zh) * | 2012-07-24 | 2012-10-31 | 河南华美生物工程有限公司 | 一种植物提取物干洗消毒凝胶 |
| CN103705539A (zh) * | 2013-12-30 | 2014-04-09 | 天津瑞普生物技术股份有限公司 | 一种猪脾转移因子制备方法 |
| CN107812137A (zh) * | 2017-10-25 | 2018-03-20 | 北京中蜜科技发展有限公司 | 一种含蜂胶的草本皮肤抑菌凝胶及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 何红梅,杨志福, 中国医药科技出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113456616A (zh) * | 2021-07-09 | 2021-10-01 | 潮州市亿生健医药保健品有限公司 | 一种基于聚六亚甲基胍的消毒用涂膜剂及其制备方法 |
| CN114832140A (zh) * | 2022-05-06 | 2022-08-02 | 江苏益仁堂生物科技有限公司 | 一种医用皮肤修复敷料配方 |
| CN118059159A (zh) * | 2024-04-22 | 2024-05-24 | 科曼尼(吉林)生物科技有限公司 | 一种中药皮肤抗菌凝胶及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113081928B (zh) | 一种植物抑菌凝胶及其制备方法和应用 | |
| CN111803624A (zh) | 一种含有转移因子的皮肤抗菌凝胶制剂和制备方法 | |
| CN101293034B (zh) | 一种治疗中耳炎的药物组合物及其制备方法 | |
| CN110960598A (zh) | 一种含艾叶提取物的天然植物抑菌软膏及其制备方法 | |
| CN118902983A (zh) | 一种壳聚糖妇科凝胶及其制备方法 | |
| CN111557877B (zh) | 一种含有积雪草提取物的牙膏及其制备方法 | |
| CN112370489A (zh) | 一种还原女性生态平衡的抑菌凝胶及其制备方法 | |
| CN108938703A (zh) | 快速抗菌的妇科凝胶 | |
| CN106902042A (zh) | 一种中药植物抑菌洗手液及其制备方法 | |
| CN111973656B (zh) | 一种含有抑菌促愈合组合物的口腔溃疡制剂 | |
| CN108079050A (zh) | 本草皮肤抑菌组合物及其制备方法与应用 | |
| CN108785374A (zh) | 清香桂皮肤抑菌凝胶及其制备方法 | |
| CN103191163B (zh) | 一种皮肤创面修复药物组合物 | |
| CN107913234A (zh) | 一种鹿茸草牙膏及其制备方法 | |
| CN114712257A (zh) | 一种含大蒜衍生物的抑菌剂及其制备方法 | |
| CN108653402A (zh) | 虎杖皮肤抑菌液 | |
| CN114129493B (zh) | 一种天麻免洗抑菌凝胶及其制备方法和应用 | |
| CN118286325B (zh) | 一种治疗微生物感染皮肤病的中药膏及其制备方法和应用 | |
| CN111773341A (zh) | 一种治疗仔猪疥癣病的复方中草药外用制剂 | |
| CN113813308A (zh) | 一种治疗烧烫伤的药物及其制备方法 | |
| CN104027298A (zh) | 一种香菇多糖凝胶剂以及制备方法 | |
| CN1095377C (zh) | 治疗皮肤癣症、炎症的药物及其制备方法 | |
| CN112472740B (zh) | 用于制备防治奶牛乳房炎的中草药复方制剂及其应用 | |
| CN100569277C (zh) | 一种治疗妇女阴道炎的泡腾片及其制备方法和用途 | |
| CN111617210B (zh) | 一种抑菌剂、制备方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201023 |
|
| RJ01 | Rejection of invention patent application after publication |